PATENT CLAIM ANALYSIS

Application Number: 15943436
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-08
Patent Classification: ["514", "009100"]

Abstract:
The invention features soluble fibroblast growth factor receptor 3 (sFGFR3) polypeptides. The invention also features methods of using sFGFR3 polypeptides to treat skeletal growth retardation disorders, such as achondroplasia.

Claim (Index 28):
The method of  claim 16 , wherein administration of the polypeptide:\n a) increases survival of the subject; b) improves locomotion of the subject; c) improves abdominal breathing in the subject; d) increases body and/or bone length of the subject; or e) improves the cranial ratio and/or restores foramen magnum shape in the subject.

Metadata:
- Claim Count in Document: 28.0
- Percentile: 91.0
- Lexical Diversity: 1.25926
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['13466672', '12784117', '13336651', '10734661', '12394756']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8062961909801298
- 35 USC 102 Novelty (BERT): 0.5373973490883341
- Combined Prediction Score: 0.7794063067909504
- Mean Citation Score: 328.42445800000013
- Max Citation Score: 338.0359
- Similarity Product: 187.56420994921925

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 0

Dataset: test